These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 36906275)

  • 21. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study.
    Caballero-Bellón M; Alonso-Saladrigues A; Bobillo-Perez S; Faura A; Arqués L; Rivera C; Català A; Dapena JL; Rives S; Jordan I
    Front Immunol; 2023; 14():1219289. PubMed ID: 37600775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.
    Major A; Collins J; Craney C; Heitman AK; Bauer E; Zerante E; Stock W; Bishop MR; Jasielec J
    Leuk Lymphoma; 2021 Jul; 62(7):1765-1769. PubMed ID: 33559517
    [No Abstract]   [Full Text] [Related]  

  • 23. Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity.
    Fugere T; Baltz A; Mukherjee A; Gaddam M; Varma A; Veeraputhiran M; Gentille Sanchez CG
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia.
    Masih KE; Ligon JA; Yates B; Shalabi H; Little L; Islam Z; Ombrello AK; Inglefield J; Nussenblatt V; Manion M; Khan J; Shah NN
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29247. PubMed ID: 34309174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms and management of CAR T toxicity.
    Ferreri CJ; Bhutani M
    Front Oncol; 2024; 14():1396490. PubMed ID: 38835382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel.
    Porter TJ; Lazarevic A; Ziggas JE; Fuchs E; Kim K; Byrnes H; Luznik L; Bolaños-Meade J; Ali SA; Shah NN; Wagner-Johnston N; Jain T
    Br J Haematol; 2022 Dec; 199(5):720-727. PubMed ID: 36111395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
    Diorio C; Shraim R; Myers R; Behrens EM; Canna S; Bassiri H; Aplenc R; Burudpakdee C; Chen F; DiNofia AM; Gill S; Gonzalez V; Lambert MP; Leahy AB; Levine BL; Lindell RB; Maude SL; Melenhorst JJ; Newman H; Perazzelli J; Seif AE; Lacey SF; June CH; Barrett DM; Grupp SA; Teachey DT
    Clin Cancer Res; 2022 Sep; 28(17):3804-3813. PubMed ID: 35705524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Need for standardization of cytokine profiling in CAR T cell therapy.
    Biery DN; Turicek DP; Diorio C; Schroeder BA; Shah NN
    Mol Ther; 2024 Sep; 32(9):2979-2983. PubMed ID: 38532629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
    Yang C; Nguyen J; Yen Y
    J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
    Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
    Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.
    Gutierrez C; Brown ART; May HP; Beitinjaneh A; Stephens RS; Rajendram P; Nates JL; Pastores SM; Dharshan A; de Moraes AG; Hensley MK; Feng L; Brudno JN; Athale J; Ghosh M; Kochenderfer JN; Arias AS; Lin Y; McEvoy C; Mead E; Westin J; Kostelecky N; Mian A; Herr MM
    Crit Care Med; 2022 Jan; 50(1):81-92. PubMed ID: 34259446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
    Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
    J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
    Gutierrez C; Brown ART; Herr MM; Kadri SS; Hill B; Rajendram P; Duggal A; Turtle CJ; Patel K; Lin Y; May HP; Gallo de Moraes A; Maus MV; Frigault MJ; Brudno JN; Athale J; Shah NN; Kochenderfer JN; Dharshan A; Beitinjaneh A; Arias AS; McEvoy C; Mead E; Stephens RS; Nates JL; Neelapu SS; Pastores SM
    J Crit Care; 2020 Aug; 58():58-64. PubMed ID: 32361219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular therapy: Immune-related complications.
    Oved JH; Barrett DM; Teachey DT
    Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.
    Yongzhi X
    Emerg Microbes Infect; 2021 Dec; 10(1):266-276. PubMed ID: 33522893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.
    Hines MR; Keenan C; Maron Alfaro G; Cheng C; Zhou Y; Sharma A; Hurley C; Nichols KE; Gottschalk S; Triplett BM; Talleur AC
    Br J Haematol; 2021 Aug; 194(4):701-707. PubMed ID: 34263927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
    Lee DW; Santomasso BD; Locke FL; Ghobadi A; Turtle CJ; Brudno JN; Maus MV; Park JH; Mead E; Pavletic S; Go WY; Eldjerou L; Gardner RA; Frey N; Curran KJ; Peggs K; Pasquini M; DiPersio JF; van den Brink MRM; Komanduri KV; Grupp SA; Neelapu SS
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):625-638. PubMed ID: 30592986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.